New insider activity at Clene ( (CLNN) ) has taken place on December 23, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Significant shareholder Chidozie Ugwumba has reduced his position in Clene by selling 9,949 shares of the company’s stock, in a transaction valued at $64,564. This move reflects a notable cash realization from his holdings and may draw attention from investors tracking insider and major shareholder activity in Clene.
Recent Updates on CLNN stock
Over the last 24 hours, Clene’s stock activity has been dominated by news of strong biomarker data for its ALS therapy candidate CNM-Au8 and the resulting shift in analyst expectations. The company reported FDA-recommended biomarker analyses showing statistically significant reductions in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in ALS patients, with the declines linked to improved survival, across both the NIH Expanded Access Program and the HEALEY ALS Platform Trial and its open-label extension. These findings are viewed as clearing a regulatory path toward an NDA filing and supporting an accelerated approval strategy, and one analyst explicitly cited this de-risking of the regulatory route and strengthened evidence of disease-modifying potential as the key reasons for upgrading their valuation outlook. At the same time, broader sentiment incorporates caution due to Clene’s weak financial profile—declining revenues, high net losses, negative equity, and a negative P/E ratio—tempering enthusiasm despite positive technical momentum and the ALS program’s progress.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
Clene’s overall stock score is primarily impacted by its poor financial performance and valuation, reflecting significant financial instability and ongoing losses. However, the positive corporate events related to promising clinical data provide a potential upside, offering hope for future growth and market positioning. The technical analysis indicates bearish momentum, further weighing down the score.
To see Spark’s full report on CLNN stock, click here.
More about Clene
YTD Price Performance: 19.48%
Average Trading Volume: 194,526
Technical Sentiment Signal: Hold
Current Market Cap: $69.03M